Vertex Pharmaceuticals Incorporated
NASDAQ · Healthcare
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||||||||||||
| Operating Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amort. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Comp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Changes in WC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing | ||||||||||||||||||
| Capital Expenditures | 437.6M | 297.7M | 200.4M | 204.7M | 235.0M | 259.8M | 75.4M | 95.4M | 99.4M | 56.6M | 45.3M | 51.2M | 51.4M | 71.1M | 34.6M | 38.1M | 23.5M | 32.2M |
| Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing | ||||||||||||||||||
| Debt Repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common Stock Issued | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Summary | ||||||||||||||||||
| Free Cash Flow | 3.19B | -790.3M | 3.34B | 3.93B | 2.41B | 2.99B | 1.49B | 1.17B | 745.5M | 179.5M | -410.7M | -624.3M | -112.1M | 196.7M | 109.1M | -673.5M | -451.1M | -258.7M |
| Net Change in Cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |